Laniado Hospital, Department of Obstetrics and Gynecology, Netanya, Israel.
Laboratory Division, Hillel Yaffe Medical Center, Hadera, Israel.
Am J Reprod Immunol. 2022 May;87(5):e13530. doi: 10.1111/aji.13530. Epub 2022 Mar 14.
The COVID-19 pandemic has many clinical manifestations. Rapid vaccine development raised concerns and speculations about future fertility outcomes and vaccine safety. We evaluated the effect of Pfizer-BioNTech mRNA SARS-CoV-2 vaccine on IVF treatment, oocyte and embryo quality, and pregnancy outcomes.
This prospective, observational cohort study was conducted in a referral IVF Unit, 3/2021-5/2021. We aimed to recruit all women undergoing IVF/ICSI cycles from 3/1-4/30/2021, 2-8 weeks after the second vaccination, and to analyze 50-60 samples in the 2-month period. Patients were categorized according to serum antibody levels: positive for spike (S), positive for nucleotide (N), or negative for both. On the day of ovum pick-up, follicular fluid and blood samples were analyzed for anti-nucleotide (anti-N) antibodies, and anti-spike (anti-S) antibodies, hormonal profile, C-reactive protein (CRP) and other metabolic parameters.
Of 59 women enrolled, 37 reported being vaccinated and 22 were not. We found 97% correlation between anti-S and anti-N in the blood and the follicular fluid. Follicular fluid was analyzed based on antibody categorization. All IVF treatment parameters in the follicular fluids and serum were comparable, except CRP was significantly elevated among patients with anti-N antibodies (2.29 [1.42-6.08] vs. 4.11 [1.62-5.75] vs. 1.44 [.36-8.33]; p < .001). Pregnancy outcomes were comparable (44% vs. 33% vs. 50%; p = .97).
mRNA SARS-CoV-2 vaccine did not appear to affect treatment outcomes or ovarian reserves in the subsequent IVF cycle.
COVID-19 大流行有许多临床表现。快速疫苗开发引发了人们对未来生育结局和疫苗安全性的担忧和猜测。我们评估了辉瑞-生物技术公司的 mRNA SARS-CoV-2 疫苗对体外受精（IVF）治疗、卵母细胞和胚胎质量以及妊娠结局的影响。
这是一项前瞻性观察性队列研究，在一个转诊 IVF 单位进行，时间为 2021 年 3 月至 5 月。我们旨在招募所有于 2021 年 3 月 1 日至 4 月 30 日期间接受 IVF/ICSI 周期的女性，在第二次接种后 2-8 周，并在 2 个月内分析 50-60 个样本。根据血清抗体水平对患者进行分类：刺突（S）阳性、核苷酸（N）阳性或两者均阴性。在取卵日，分析卵泡液和血液样本中的抗核苷酸（抗-N）抗体和抗刺突（抗-S）抗体、激素谱、C 反应蛋白（CRP）和其他代谢参数。
在 59 名入组的女性中，有 37 名报告接种了疫苗，22 名未接种疫苗。我们发现血液和卵泡液中的抗-S 和抗-N 之间有 97%的相关性。根据抗体分类分析卵泡液。卵泡液和血清中的所有 IVF 治疗参数均相似，但抗-N 抗体患者的 CRP 显著升高（2.29 [1.42-6.08] vs. 4.11 [1.62-5.75] vs. 1.44 [.36-8.33]；p < 0.001）。妊娠结局相似（44% vs. 33% vs. 50%；p = 0.97）。
mRNA SARS-CoV-2 疫苗似乎不会影响随后的 IVF 周期中的治疗结局或卵巢储备。
